Phase Ⅱ/Ⅲ Clinical Study of Tumor Treating Fields （EFE-P100）Combined With Docetaxel in the Treatment of Stage IV Non-small Cell Lung Cancer Patients With Disease Progression After Platinum-based Chemotherapy and Anti-programmed Death 1（PD-1)/Programmed Cell Death-Ligand 1(PD-L1) Antibody Treatment
Clinical trial NCT05661240 · UNKNOWN
Trial details
- NCT number
- NCT05661240
- Sponsor
- Jiangsu Healthy Life Innovation Medical Technology Co., Ltd
- Status
- UNKNOWN
- Phase
- Phase 2, Phase 3
- Study type
- INTERVENTIONAL
- Start date
- 2022-12-20
- Primary completion
- 2024-05-25
- Enrollment
- 348
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.